SpaceX reports as a public company for the first time. The headline figures, a profitable Starlink and a large consolidated loss, are both already expected and priced in, telling investors almost nothing about whether the $1.77 trillion valuation is justified.
Palantir has beaten earnings estimates eight straight quarters, yet the stock is down roughly 40% from its peak. The published consensus bar and the valuation bar embedded in the price are different things, and beating the first says nothing about clearing the second.
HOA foreclosure filings are up nearly 40% in two years. The disproportion between a trivial trigger debt and a home-destroying consequence isn't an accident, it's built into a fee-collection machinery that rewards the lawyers who escalate it.
Retail AI trading bots are marketed as handing individuals a hedge fund's algorithm. What made quant funds successful was never the algorithm alone, it was proprietary data, execution speed, capital, and an ongoing research process, none of which comes in a consumer product.
A bipartisan Senate funding bill would temporarily block a White House proposal giving political appointees control over individual federal research grants. The real fight is about which level of the decision political accountability should reach, not whether it belongs at all.
SpaceX shares hit a record low right before its first earnings report and IPO lockup expiration. Separating the lockup's mechanical supply pressure from genuine fundamental concerns is the difference between reading the price as a verdict and reading it correctly.
A single injection has cured syphilis for eighty years, yet congenital syphilis rates have risen more than 200% in five years. A national penicillin shortage, no substitute drug for pregnant patients, and gaps in surveillance explain why.
Two FDA advisory committees faced imperfect evidence for two drugs in the same week and split in opposite directions. The deciding factor wasn't how much proof each had, but whether the proof could be believed.
The American Diabetes Association defended a journal's editorial independence in 2015 when it was cheap. In 2026 it suppressed its own researchers when defending them risked its NIH funding relationship.
Federal agencies say essential disease monitoring remains intact. Specialists warn that reduced staffing could make emerging threats harder to detect.
Read the ArticleEvery article on Mavengity is written by a dedicated topic desk and checked against current market practice.
Home, auto, life, and health coverage, explained clearly and checked against the fine print.
Browse InsuranceRates, refinancing, and first-time buyer strategy, without the jargon lenders assume you already know.
Browse MortgageBudgeting, saving, and everyday money habits that compound. No get-rich-quick promises.
Browse Personal FinanceContracts, consumer rights, and disputes, explained so you know where you stand.
Browse LegalHealth coverage and medical billing, broken down so surprise bills are less likely to surprise you.
Browse HealthcareWe start from public rate filings, regulator guidance, and lender disclosures, not marketing copy.
If a term needs a footnote, we explain it in the sentence instead of hiding it in the fine print.
We flag trade-offs and blind spots, not just the upside, so you get the full picture before you decide.
Mavengity is reader-supported and editorially independent from the products we cover.